Treatment Options for Patients with Brain Metastatic Disease in HER2-Positive Breast Cancer

Manikandan Dhanushkodi

doi:10.4103/ijmpo.ijmpo_98_20

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(05): 735-737
DOI: 10.4103/ijmpo.ijmpo_98_20

Courting Controversy

Treatment Options for Patients with Brain Metastatic Disease in HER2-Positive Breast Cancer

Manikandan Dhanushkodi

Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India

› Author Affiliations

Abstract

Full Text

References

References
1 Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2020; 21: 519-30
2 Yardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M. et al. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer 2014; 110: 2756-64
3 Murthy R, Borges VF, Conlin A, Chaves J, Chamberlain M, Gray T. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol 2018; 19: 880-8
4 Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA. et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 2020; 382: 597-609
5 Borges VF, Ferrario C, Aucoin N, Falkson C, Khan Q, Krop I. et al. Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer: A phase 1b clinical trial. JAMA Oncol 2018; 4: 1214-20
6 Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. New England J Med 2019; 382: 610-21
7 Saura C, Oliveira M, Feng YH, Dai MS, Hurvitz SA, Kim SB. Neratinib+capecitabine versus lapatinib+capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. JCO 2019; 37: 1002
8 Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G. et al. Neratinib plus paclitaxel vs. trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: The NEfERT-T randomized clinical trial. JAMA Oncol 2016; 2: 1557-64
9 Ma F, Ouyang Q, Li W, Jiang Z, Tong Z, Liu Y. et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: A randomized, phase II study. J Clin Oncol 2019; 37: 2610-9
10 Blair HA. Pyrotinib:First global approval. Drugs 2018; 78: 1751-5
11 Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J. Trastuzumab emtansine for HER2-positive advanced breast cancer. New England J Med 2012; 367: 1783-91
12 Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F. et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study. Lancet Oncol 2013; 14: 64-71
13 Parsai S, Miller JA, Juloori A, Chao ST, Kotecha R, Mohammadi AM. et al. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases. J Neurosurg 2019; 132: 503-11
14 Rugo HS, Im SA, Wright GL, Escriva-de-Romani S, DeLaurentiis M, Cortes J. SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M)+ chemotherapy (C) versus trastuzumab (T)+C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx). JCO 2019; 37: 1000
15 Saura C, Thistlethwaite F, Banerji U, Lord S, Moreno V, MacPherson I. A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer. JCO 2018; 36: 1014